Agenus (NASDAQ: AGEN) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Agenus to similar companies based on the strength of its institutional ownership, risk, profitability, valuation, analyst recommendations, earnings and dividends.
Insider and Institutional Ownership
37.9% of Agenus shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 7.9% of Agenus shares are owned by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Agenus and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agenus||$22.57 million||-$126.99 million||-3.36|
|Agenus Competitors||$217.28 million||-$39.39 million||-70.79|
Agenus’ peers have higher revenue and earnings than Agenus. Agenus is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Agenus and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Agenus has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Agenus’ peers have a beta of 1.50, indicating that their average share price is 50% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Agenus and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agenus presently has a consensus price target of $6.33, indicating a potential upside of 61.15%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.04%. Given Agenus’ stronger consensus rating and higher possible upside, analysts plainly believe Agenus is more favorable than its peers.
Agenus Company Profile
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.